These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33554103)

  • 21. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.
    Löscher W; Gillard M; Sands ZA; Kaminski RM; Klitgaard H
    CNS Drugs; 2016 Nov; 30(11):1055-1077. PubMed ID: 27752944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brivaracetam augments short-term depression and slows vesicle recycling.
    Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
    Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levetiracetam inhibits THP-1 monocyte chemotaxis and adhesion via the synaptic vesicle 2A.
    Zhang Y; Hu M; Tang YY; Zhang B; Han YY; Huang ZY; Chen C; Li G
    Biochem Biophys Res Commun; 2020 Feb; ():. PubMed ID: 32067739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dramatic effect of levetiracetam in early-onset epileptic encephalopathy due to STXBP1 mutation.
    Dilena R; Striano P; Traverso M; Viri M; Cristofori G; Tadini L; Barbieri S; Romeo A; Zara F
    Brain Dev; 2016 Jan; 38(1):128-31. PubMed ID: 26212315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential expression of synaptic vesicle protein 2A after status epilepticus and during epilepsy in a lithium-pilocarpine model.
    Contreras-García IJ; Pichardo-Macías LA; Santana-Gómez CE; Sánchez-Huerta K; Ramírez-Hernández R; Gómez-González B; Rocha L; Mendoza Torreblanca JG
    Epilepsy Behav; 2018 Nov; 88():283-294. PubMed ID: 30336420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.
    Surges R; Volynski KE; Walker MC
    Ther Adv Neurol Disord; 2008 Jul; 1(1):13-24. PubMed ID: 21180561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seletracetam enhances short term depression in vitro.
    Yang X; Meehan AL; Rothman SM; Dubinsky JM
    Epilepsy Res; 2015 Nov; 117():17-22. PubMed ID: 26320080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levetiracetam efficacy in children with epilepsy with electrical status epilepticus in sleep.
    Chen J; Cai F; Jiang L; Hu Y; Feng C
    Epilepsy Behav; 2015 Mar; 44():73-7. PubMed ID: 25632834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levetiracetam.
    Krishna K; Raut AL; Gohel KH; Dave P
    J Assoc Physicians India; 2011 Oct; 59():656-8. PubMed ID: 22479748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy].
    Tokudome K; Shimizu S; Serikawa T; Ohno Y
    Nihon Yakurigaku Zasshi; 2018; 152(6):275-280. PubMed ID: 30531097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy.
    Glien M; Brandt C; Potschka H; Löscher W
    Epilepsia; 2002 Apr; 43(4):350-7. PubMed ID: 11952764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.
    Shi J; Zhou F; Wang LK; Wu GF
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.
    de Groot M; Toering ST; Boer K; Spliet WG; Heimans JJ; Aronica E; Reijneveld JC
    Neuro Oncol; 2010 Mar; 12(3):265-73. PubMed ID: 20167814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.
    Daniels V; Wood M; Leclercq K; Kaminski RM; Gillard M
    Br J Pharmacol; 2013 Jul; 169(5):1091-101. PubMed ID: 23530581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of tolerance to levetiracetam in rats with chronic epilepsy.
    van Vliet EA; van Schaik R; Edelbroek PM; da Silva FH; Wadman WJ; Gorter JA
    Epilepsia; 2008 Jul; 49(7):1151-9. PubMed ID: 18266746
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.